Aristada is a long-acting injectable antipsychotic medication approved by the FDA for the treatment of schizophrenia in adults. Unlike daily pills, Aristada is given as an injection at a healthcare provider’s office on a schedule that ranges from once a month to once every two months, depending on the dose. It is only approved for adults aged 18 and older.
How Aristada Treats Schizophrenia
Aristada contains aripiprazole lauroxil, which is a prodrug. That means the medication itself isn’t active when injected. Once inside the body, it slowly converts into aripiprazole, the same active ingredient found in the widely known oral antipsychotic Abilify. Aripiprazole works by regulating dopamine and serotonin activity in the brain, helping reduce hallucinations, disorganized thinking, and other symptoms of schizophrenia.
What makes Aristada distinctive is how long it stays in the body. After an injection, the medication absorbs over roughly 46 days, with a lag time of about three days before it begins entering the bloodstream. The elimination half-life (how long it takes for half the drug to leave your system) ranges from about 54 to 57 days depending on the dose. This extended timeline is what allows for less frequent dosing compared to daily oral medication.
Who Aristada Is and Isn’t For
Aristada is approved exclusively for schizophrenia in adults. It is not approved for bipolar disorder, depression, or any other psychiatric condition. It has not been evaluated for safety or effectiveness in patients under 18 or over 65.
The medication carries a serious warning: it is not approved for treating psychosis related to dementia. Older adults with dementia-related psychosis who take antipsychotic medications face an increased risk of death. This is a class-wide concern for all antipsychotic drugs, not unique to Aristada.
How Treatment Starts
Starting Aristada is more involved than simply getting a first injection. Because the medication takes several days to begin releasing into the bloodstream, a gap exists where you wouldn’t have therapeutic drug levels. To bridge that gap, there are two initiation options.
The first uses a companion product called Aristada Initio, a one-time injection given alongside a single dose of oral aripiprazole on the same day. The second option skips Aristada Initio and instead requires 21 consecutive days of oral aripiprazole overlapping with the first Aristada injection. Either way, the goal is to make sure you have consistent medication coverage from day one. By comparison, the similar injectable Abilify Maintena requires a 14-day oral overlap.
Dosing and Injection Schedule
Aristada comes in several dose strengths, and the dose determines how often you need an injection. A 441 mg dose is given monthly. An 882 mg dose can be given monthly or every six weeks. A 1,064 mg dose is given every two months. This flexibility is one practical advantage over Abilify Maintena, which is only available as a monthly injection.
The injection goes into a large muscle. The 441 mg dose can be given in either the upper arm (deltoid) or the buttock (gluteal) muscle. All other doses go into the gluteal muscle only. Each injection is administered by a healthcare professional; this is not a medication you can give yourself at home.
How Aristada Compares to Abilify Maintena
Both Aristada and Abilify Maintena deliver aripiprazole through a long-acting injection, but they differ in important ways. Abilify Maintena contains aripiprazole directly, while Aristada uses the prodrug form that converts to aripiprazole after injection. Abilify Maintena is FDA-approved for both schizophrenia and bipolar I disorder, while Aristada is approved only for schizophrenia.
The biggest practical difference is scheduling flexibility. If monthly visits to a provider’s office are difficult to maintain, Aristada’s six-week and two-month dosing options can reduce the number of appointments. For someone who struggles with daily pill adherence, either long-acting injectable can remove that burden entirely.
Common Side Effects
The most frequently reported side effect in clinical trials was akathisia, a restless, uncomfortable urge to move, which occurred in about 6% of patients (compared to lower rates on placebo). Other side effects occurring in 2% or more of patients included injection site pain, weight gain, headache, insomnia, and restlessness.
Injection site reactions affected 4% to 5% of patients depending on the dose, compared to 2% on placebo. Most of these were pain at the injection site rather than more serious reactions. Movement-related side effects beyond akathisia occurred in 5% to 7% of patients on Aristada versus 4% on placebo. These can include muscle stiffness, tremor, or slow movement.
Weight gain is worth monitoring over time, as it’s a known concern with many antipsychotic medications. Your provider will typically track your weight and metabolic markers like blood sugar and cholesterol at regular intervals.
Why Long-Acting Injectables Matter for Schizophrenia
Schizophrenia is a condition where consistent medication use makes a significant difference in preventing relapses. Missing doses of oral medication is common, sometimes because of side effects, sometimes because the nature of the illness itself makes it hard to stick with a daily routine. Long-acting injectables like Aristada turn a daily decision into a monthly or bimonthly appointment, which for many people translates into more stable symptom control and fewer hospitalizations.
The tradeoff is less flexibility. If you experience a side effect from a daily pill, you can stop taking it. With Aristada, the medication stays in your system for weeks after an injection, so side effects can’t be quickly reversed. This is why most providers will have you try oral aripiprazole first to confirm you tolerate it before switching to the long-acting injectable form.